Pay in 4 interest-free payments of $7.39 Learn more
Ships within 48 hours · Estimated delivery Oct 11 - Oct 16
For growth hormone secretagogues like tesamorelin, the research is inconclusive
Ribas GS, Vargas CR, Wajner M
The most robust evidence to date comes from the phase 2 randomised controlled trial (Jastreboff et al., NEJM , 2023)
concomitant risk factors (hypertension, dyslipidemia), diabetic complications (peripheral artery disease, myocardial infarction, ischemic heart disease, stroke or transient ischemic attackTIA, heart failure, cardiovascular disease, neurological complications, ocular complications, renal complications, chronic kidney diseaseCKD), history of severe hypoglycemia, other comorbidities (chronic pulmonary disease, systemic inflammatory disease, cancer), the Charlson comorbidity (derived from administrative claims as previously described [24, 25]), the number of different A10B-class drugs (blood glucose lowering drugs, excluding insulins), use of glucose lowering medications in the year before the index date (metformin, sulfonylureas, SGLT-2i, pioglitazone), and use of other drugs in the year before the index date (ACE inhibitors, diuretics, beta blockers, other blood pressure lowering drugs, statins, fibrates or omega-3, PCSK9 inhibitors, ezetimibe, and anti-platelet agents)
We'll look at ongoing research, emerging trends, and how this approach fits into the broader landscape of obesity treatment
US$ 23.82
US$ 29.97
US$ 23.85
